immune
Thymus / immune
Thymic and immune papers — short peptides written for the thymus and the cells it educates.
This chapter is the thymus and the immune questions attached to it. Thymic involution with age is a long-running subject in gerontology; the Khavinson lineage includes thymic extracts and short peptides designed after that tissue. Papers belong here when the thymus, or the immune cells that tissue is asked to educate, is the organ of record.
Peptide themes that belong on this hub are thymic extracts and short-chain analogs from that line (names you will meet include Thymalin, Thymogen, and Vilon, among others). Adjacent themes include immune-cell cultures and clinical communications that name the thymus or immune function as the target. A paper about infection that never names a thymic peptide does not belong on this shelf.
Read linked studies as reports, not as immune “support.” Note whether the work is culture, animal, or human, and how large the claim is. Follow the PMID. This publication does not diagnose immunodeficiency or recommend a product.
Studies
- The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.
Docking, pathway analysis, and an LPS-stimulated PBMC assay in which Thymalin, KE (Vilon), and EW (Thymogen) lowered IL-1β, IL-6, and TNF-α — not clinical evidence that these peptides treat COVID-19.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
In PMA-differentiated THP-1 monocytes, five Khavinson peptides increased kinase tyrosine phosphorylation and, after LPS, lowered TNF and IL-6; Chonluten also cut TNF from LPS-exposed monocytes, and peptide-treated cells adhered less to activated HUVECs.
- Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19
An open-label, single-center randomized hospital series (n=42 Thymalin + standard care vs n=50 standard care) reported a faster fall in IL-6, CRP, D-dimer, and some T-cell indices; it is not evidence that Thymalin treats COVID-19.
- Peptide Regulation of Cell Differentiation.
A 2020 catalog of short peptides proposed to direct stem-cell differentiation by sequence; KEDG is listed among immune-cell differentiators, not as a gonad peptide — a review hypothesis, not a trial.
- Peptides: Prospects for Use in the Treatment of COVID-19
A 2020 open-access review of peptide candidates for COVID-19 research — not a clinical trial, and not evidence that these peptides treat the disease.
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people
In cultured lymphocytes from donors aged 76–81, Vilon 0.01 µg/ml was reported to decondense facultative heterochromatin and reactivate nucleolus-organizer ribosomal genes, without opening pericentromeric C-heterochromatin.
- Peptides of pineal gland and thymus prolong human life.
A 6–8-year clinical assessment of Thymalin and Epithalamin in 266 elderly people; PubMed tags the paper as an RCT, but the English abstract does not describe randomization or blinding.